Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 207

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles

Open access
Syed, Abdullah M., Ciling, Alison, Taha, Taha Y., Chen, Irene P., Khalid, Mir M., Sreekumar, Bharath, Chen, Pei-Yi, Kumar, G. Renuka, Suryawanshi, Rahul, Silva, Ines, Milbes, Bilal, Kojima, Noah, Hess, Victoria, Shacreaw, Maria, Lopez, Lauren, Brobeck, Matthew, Turner, Fred, Spraggon, Lee, Tabata, Takako, Ott, Melanie, Doudna, Jennifer A. · 2022 · Proceedings of the National Academy of Sciences

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant contains extensive sequence changes relative to the earlier-arising B.1, B.1.1, and Delta SARS-CoV-2 variants that have unknown effects on viral infectivity and response to existing vaccines. Using SARS-CoV-2 virus-like particles (VLPs), we examined mutations in all four structural proteins and found that Omicron and Delta showed 4.6-fold higher luciferase delivery overall relative to the ancestral B.1 lineage, a property conferred mostly by enhancements in the S and N proteins, while mutations in M and E were mostly detrimental to assembly. Thirty-eight antisera samples from individuals vaccinated with Pfizer/BioNTech, Moderna, or Johnson & Johnson vaccines and convalescent sera from unvaccinated COVID-19 survivors had 15-fold lower efficacy to prevent cell transduction by VLPs containing the Omicron mutations relative to the ancestral B.1 spike protein. A third dose of Pfizer vaccine elicited substantially higher neutralization titers against Omicron, resulting in detectable neutralizing antibodies in eight out of eight subjects compared to one out of eight preboosting. Furthermore, the monoclonal antibody therapeutics casirivimab and imdevimab had robust neutralization activity against B.1 and Delta VLPs but no detectable neutralization of Omicron VLPs, while newly authorized bebtelovimab maintained robust neutralization across variants. Our results suggest that Omicron has similar assembly efficiency and cell entry compared to Delta and that its rapid spread is due mostly to reduced neutralization in sera from previously vaccinated subjects. In addition, most currently available monoclonal antibodies will not be useful in treating Omicron-infected patients with the exception of bebtelovimab.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.2200592119

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 207

Metadata

Authors
Syed, A. M., Ciling, A., Taha, T. Y., Chen, I. P., Khalid, M. M., Sreekumar, B., Chen, P.-Y., Kumar, G. R., Suryawanshi, R., Silva, I., Milbes, B., Kojima, N., Hess, V., Shacreaw, M., Lopez, L., Brobeck, M., Turner, F., Spraggon, L., Tabata, T., Ott, M., & Doudna, J. A.
Venue
Proceedings of the National Academy of Sciences
Published
2022-07-19
Volume
119
Issue
31
Pages
e2200592119-e2200592119
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W4286218372
Cited by
207
References
2
FWCI
22.34
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. https://app.cochat.ai/papers/10.1073/pnas.2200592119
The paper
Syed, A. M., Ciling, A., Taha, T. Y., Chen, I. P., Khalid, M. M., Sreekumar, B., Chen, P.-Y., Kumar, G. R., Suryawanshi, R., Silva, I., Milbes, B., Kojima, N., Hess, V., Shacreaw, M., Lopez, L., Brobeck, M., Turner, F., Spraggon, L., Tabata, T., . . . Doudna, J. A. (2022). Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2200592119

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.